Skip to main content
Premium Trial:

Request an Annual Quote

After Shareholder Vote, Arris s Acquisition of Sequana Therapeutics Is Concluded


SOUTH SAN FRANCISCO, Calif.--After shareholders of Sequana Therapeutics voted overwhelmingly in favor of the move earlier this month, Arris Pharma ceutical here has completed its acquisition of the leading genomics firm, with the new, combined entity taking on the name AxyS Pharmaceuticals. Then on January 14, AxyS announced that it has launched a new Advanced Tech nologies Division to focus on commercializing the company's capabilities in combinatorial chemistry, pharmacogenomics, and its patented Delta technology.

AxyS also named Robert Reed, formerly the company's senior director of business development, as vice-president and divisional manager for the new group. Douglas Livingston will serve as divisional vice-president for combinatorial chemistry.

According to the two companies, AxyS aims to be a leader in the integration of drug discovery technologies, from gene identification through clinical development. In particular, the firm will focus on the discovery of small-molecule therapeutics. Sequana used industrial-scale gene discovery and functional genomics technologies, including a strong bioinformatics component, to help develop therapeutic and diagnostic products. Thanks to deals signed previously by Arris and Sequana, AxyS has research collaborations with several major pharmaceutical and biotech companies in such areas as respiratory, cardiovascular, metabolic, and infectious disease, as well as oncology and central nervous system disorders.

The former Sequana entity, which employs approximately 200, will continue operations as a wholly owned subsidiary at its La Jolla, Calif., headquarters and at its NemaPharm subsidiary in Cambridge, Mass. Sequana shareholders held a special meeting January 7 to vote on the proposal. Reportedly, over 93 percent approved the merger.

Filed under

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.